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ABSTRACT
Cell quiescence is controlled by regulated genome-encoded programs that actively 
express genes which are often down-regulated or inactivated in transformed cells. 
Among them is FoxO1, a transcription factor that imposes quiescence in several cell 
types, including T lymphocytes. In these cells, the FAM65B encoding gene is a major 
target of FOXO1. Here, we show that forced expression of FAM65B in transformed cells 
blocks their mitosis because of a defect of the mitotic spindle, leading to G2 cell cycle 
arrest and apoptosis. Upon cell proliferation arrest, FAM65B is engaged in a complex 
containing two proteins well known to be involved in cell proliferation i.e. the HDAC6 
deacetylase and the 14.3.3 scaffolding protein. In primary T cells, FAM65B is down-
regulated upon T cell receptor engagement, and maintaining its expression blocks 
their proliferation, establishing that the decrease of FAM65B expression is required 
for proliferation. Conversely, inhibiting FAM65B expression in naive T lymphocytes 
decreases their activation threshold. These results identify FAM65B as a potential new 
target for controlling proliferation of both transformed and normal cells.
INTRODUCTION
Before encountering foreign antigens, naive T 
lymphocytes do not proliferate. It was initially assumed 
that this “default” state reflected the absence of activating 
signals [1]. It is now known that the steady-state 
maintenance of naive T cells is an active state and depends 
on a combination of signals from the IL-7 receptor and 
the T cell antigen receptor (TCR) triggered by major 
histocompatibility complex (MHC) molecules loaded with 
self-peptides [2, 3]. Paradoxically, the same signals lead 
to a loss of quiescence of naive T cells in some situations 
such as lymphopenia, and result in entry into the cell cycle 
(lymphopenia-induced proliferation) and acquisition of 
memory-like markers [2, 3]. Therefore, naive T cells are 
somehow restrained in proliferation, but this restraint can 
be alleviated by external cues. The molecular mechanisms 
underlying such restraint have proven elusive.
The forkhead box O1 (FoxO1) transcription factor 
is involved in the maintenance of the quiescence state of 
T cells [4]. The FoxO family is the mammalian orthologue 
of the c-elegans protein DAF16, and has an evolutionarily 
conserved function in the adaptation of proliferation-to-
nutrient availability [5]. In quiescent T cells, FoxO1 is 
nuclear, and binds DNA. This DNA binding drives the 
transcription of several genes that encode proteins involved 
in cell mobility, cell survival and quiescence. Upon TCR 
stimulation, FOXO1 is phosphorylated by Akt kinase 
under the control of the phospho-inositide 3 kinase (PI3K) 
pathway, leading to its nuclear exclusion and an arrest of 
its transcriptional activity [6, 7]. Conditional deletion of 
Foxo1 in mouse T cells results in spontaneous activation of 
T cells with an activated-memory phenotype [8].
We previously identified family with sequence 
similarity 65, member B (FAM65B; previously known 
as C6ORF32, KIAA0386 or PL48), as a transcriptional 
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target of FOXO1 in T cells [7, 9]. Two main isoforms 
of FAM65B proteins are expressed in T cells and have 
been functionally characterized as an atypical inhibitor 
of the small G protein RhoA [9, 10]. FAM65B has also 
been described to induce neurite-like outgrowths in 
HEK293 and C2C12 cells probably through an action 
on microtubules [11]. This step appears to be involved in 
myoblast fusion and differentiation [12]. More recently, 
the protein has been shown to be a component of hair cell 
stereocilia, an actin-rich structure required for hearing 
[13]. The FAM65B protein does not seem to be endowed 
with intrinsic enzymatic properties. Instead, its functional 
effect in cell mobility seems to rely on its interaction 
with the small G protein RhoA [9, 10], whereas its role 
in myoblast differentiation is dependent on its interaction 
with a complex containing the histone deacetylase HDAC6 
and 14.3.3 proteins [10, 12]. The 14.3.3 proteins are a 
family of regulatory signaling molecules that interact with 
other proteins in a phosphorylation-dependent manner 
and function as adapter or scaffold proteins in signal 
transduction pathways [14]. Although 14.3.3 proteins 
act in cell signaling, cell cycle control, and apoptotic cell 
death, a large group of 14.3.3 -binding partners have been 
described to regulate cytoskeleton architecture [15].
We now report that FAM65B can act as a molecular 
switch controlling quiescence of normal T cells and 
proliferation of malignant cell lines. Analyzing the 
mechanism responsible for this effect, we show that 
proliferating cells are blocked in mitosis due to a defect of 
the mitotic spindle triggered by FAM65B overexpression. 
We also demonstrate at the molecular level that FAM65B 
forms a molecular complex with HDAC6 and 14.3.3, and 
that this tripartite complex is required for proliferation 
arrest. We also show that quiescent T lymphocytes express 
high levels of FAM65B and that a rapid down-regulation 
of the molecule is necessary to enable T cells to divide in 
response to TCR engagement. Accordingly, we also show 
that FAM65B cellular levels set the activation threshold of 
T cells required to start a substantial proliferation.
RESULTS
FAM65B inhibits the proliferation of human 
leukemic T cells
FAM65B is transcriptionally controlled by FOXO1 
[9]. In the Jurkat leukemic T cell line, where the PI3K 
pathway is constitutively active, FOXO1 is permanently 
shut-down and so degraded [16] (Supplementary Figure 
S1A, lane 2), and the two isoforms of FAM65B are not 
expressed ([7, 9], Supplementary Figure S1B, lane 1). 
We therefore used these cells to follow how FAM65B 
re-expression could affect their growth. Cells were 
transfected with expression constructs coding for GFP 
alone as a control, or for FAM65B isoform 2 fused to GFP. 
Having confirmed that FAM65B re-expression did not alter 
FOXO1 expression level (Supplementary Figure S1A, 
lane 2 and 3), we monitored the proliferation by counting 
the total viable cell number daily, and quantifying the 
percentage of GFP+ cells by flow cytometry. In contrast 
to control cells, the number of FAM65B expressing cells 
did not increase over time (Figure 1A). The same effect 
was observed when FAM65B isoform 1 fused to GFP was 
expressed (data not shown). Analysis of the cell cycle 
demonstrated that FAM65B expression results in a G2/M 
accumulation after 3 days of culture, with 47 ± 7% (mean 
± SD) of FAM65B positive vs 22 ± 1.4% of control cells 
in G2/M phase (Figure 1B and 1C). In addition, annexin 
V labelling revealed that the percentage of dying cells was 
significantly increased by FAM65B (Figure 1D).
FAM65B is a mitotic inhibitor that alters the 
formation of the mitotic spindle
In order to study in detail the mechanism of this 
FAM65B-induced growth arrest, we used the classic 
model of adherent HeLa cancer cell line. HeLa cells, 
as all cell lines that we have tested including HEK293, 
NIH3T3 and CEM cells, do not express FAM65B (data 
not shown). We first show that, as observed in Jurkat cells, 
FAM65B expression led to an increase of HeLa cells in 
G2/M phase (55% vs 29% in control cells; Figure 2A). 
Next, in order to analyze how FAM65B might disturb 
the mitotic process, we co-transfected HeLa cells with 
vectors coding for GFP alone or FAM65B-GFP, and 
histone H2B-mCherry, to monitor the dynamics of DNA 
reorganization during mitosis. Whereas cells transfected 
with GFP alone completed mitosis in 43 ± 9 min, the 
time required for mitosis of FAM65B-expressing cells 
was more variable and longer (94 ± 65 min, Figure 2B 
and 2D). Chromosomes in the control cell were perfectly 
aligned on the metaphase plate 16 ± 5 min after initiation 
of cell division, as determined by cell rounding (Figure 2C 
and 2D). In contrast, FAM65B-expressing cells were not 
able to align chromosomes correctly, leading to abnormal 
anaphases with frequent lagging chromatids after more 
than 20 min for 37% of the cells, and more than 40 min 
for 14% of the cells (Figure 2C and 2D).
Chromosome movements during mitosis rely upon a 
complex macromolecular machinery known as the mitotic 
spindle. The spindle has three principal components, 
centrosomes, microtubules composed of α-tubulin, 
and chromosomes [17]. Since FAM65B is described 
as regulating the elongation of microtubules [18], we 
supposed that FAM65B expression might perturb the 
formation of the mitotic spindle. To test this hypothesis, 
we co-transfected HeLa cells with vectors coding for GFP 
alone or FAM65B-GFP, and α-tubulin-mCherry, to follow 
the microtubule network during mitosis. We observed 
that, whereas cells transfected with GFP alone were able 
to form a mitotic spindle, FAM65B-expressing cells 
presented an aberrant tubulin network with an absence of 
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clear mitotic spindle (Figure 2E). These results show that 
FAM65B expression disturbs the formation of the mitotic 
spindle, resulting in mitotic failure.
The FAM65B/HDAC6/14.3.3 tripartite complex 
is required for proliferation arrest
We then examined the implication of known targets 
of FAM65B in the molecular mechanism of growth arrest. 
We have previously shown that FAM65B binds directly 
and inhibits RhoA [9], a protein that has been involved 
in cytokinesis [19]. We hypothesized that the effect of 
FAM65B on proliferation could be due to this interaction. 
Therefore, we constructed a plasmid coding for a mutant 
version of FAM65B unable to bind RhoA (RL151-152AA, 
[10] and Figure 3A). Upon transfection, this mutant 
was still able to inhibit proliferation of Jurkat T cells as 
efficiently as the wild type FAM65B protein, thus showing 
that the anti-proliferative activity of FAM65B was not due 
to its RhoA inhibitory activity (Figure 3B). 
It has been shown that the phosphorylated form of 
FAM65B can interact with 14.3.3, a family of proteins that 
bind to phospho-Serine and phospho-Threonine residues 
and play important roles in various processes, including in 
coordinating cell cycle progression [14]. As FAM65B has 
been described as a phosphorylated protein in neutrophils 
[10], we examined its phosphorylation status in Jurkat T 
cells by treating whole cell extracts with λ-phosphatase.
We observed a decrease of the apparent molecular weight 
of the protein (Supplementary Figure S1B), suggesting 
that FAM65B is also phosphorylated in these cells. A 
previous report has shown that a mutant form of FAM65B 
with serine residues mutated to alanine at positions 21, 
37, 341, 523, and 535, (hereafter called FAM65B S(x5)
A) did not bind 14.3.3 anymore [10], see also Figure 3C). 
We therefore investigated whether this mutant could have 
an anti-proliferative effect. We observed that the S(x5)
A phosphorylation mutant of FAM65B lost its capacity 
to inhibit the proliferation of Jurkat cells (Figure 3D). 
Therefore, the phosphorylation of FAM65B and its 
interaction with 14.3.3 is required for its anti-proliferative 
activity. 
It has been stated that (i) 14.3.3 is a molecular 
partner of HDAC6 [20], (ii) inhibition of the deacetylase 
Figure 1: FAM65B expression inhibits cell proliferation by perturbing mitosis stage. (A) Jurkat cells were transfected either 
with GFP or FAM65B fused with GFP expression vectors and their proliferation was measured by counting the total viable cell number at 
the indicated time points. (B) The cell cycle profile was evaluated by flow cytometry three days after transfection. (C) The proportion of 
transfected Jurkat cells in G2/M phase was estimated daily by flow cytometry. (D) The proportion of annexin V-labeled cells was measured 
daily by flow cytometry. Results are shown as means ± SD of at least three individual experiments. Statistical analysis: Paired two-tailed 
Student’s t-test.
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activity of HDAC6 leads to inhibition of cell proliferation, 
and (iii) FAM65B inhibits the deacetylase activity of 
HDAC6 [12]. We therefore speculated that the anti-
proliferative effect of FAM65B might rely on its 
capacity to inhibit HDAC6 through its interaction with 
14.3.3. To test this hypothesis, we first tried to reverse 
the anti-proliferative effect of FAM65B by an excess of 
HDAC6 in FAM65B-arrested Jurkat cells. The results 
showed that an excess of HDAC6 was able to partially 
override the FAM65B-induced proliferation arrest 
(Figure 3E). Conversely, inhibition of HDAC6 with a 
pharmacological inhibitor dose-dependently inhibited 
the growth of Jurkat cells and induced a marked G2/M 
arrest, mimicking the effect of FAM65B (Supplementary 
Figure S2A), in a similar fashion to what is normally 
observed with etoposide (Supplementary Figure S3). We 
next assessed the interaction between FAM65B, 14.3.3, 
and HDAC6, and the role of FAM65B phosphorylation in 
these interactions. To do this, we co-transfected HDAC6 
and 14.3.3 with wild type or S(x5)A form of FAM65B. 
Whereas HDAC6 and 14.3.3 co-immunoprecipitate with 
the wild-type form of FAM65B (Figure 3F, lane 1), the 
mutated form of FAM65B was unable to interact with 
these two partners (Figure 3F, lane 2). These results 
suggest that the anti-proliferative property of FAM65B 
results from the capacity of its phosphorylated form to 
interact with HDAC6 and 14.3.3.
FAM65B controls T cell proliferation upon TCR 
stimulation
We next analysed the consequences of the regulation 
of cell division by FAM65B upon physiological T cell 
activation. We first followed the expression level of 
FAM65B in T cells upon TCR triggering to see whether 
it was subject to variations after stimulation. FAM65B 
expression was quantified at the transcript and protein 
levels, following in vitro stimulation of primary human 
T lymphocytes with anti-CD3 and -CD28 coated beads. 
FAM65B transcripts decreased quickly upon TCR 
stimulation (Figure 4A), in line with a general and 
early block in FOXO1-mediated transcription upon 
antigen recognition [6]. Both FAM65B isoforms show a 
simultaneous loss, which was complete 24 hours after the 
Figure 2: FAM65B expression disrupts the formation of the mitotic spindle, resulting in mitotic failure. (A) The cell 
cycle of HeLa cells transfected with GFP alone or FAM65B fused with GFP expression vectors was analyzed by flow cytometry two 
days after transfection. Results are representative of three experiments. The time required for each HeLa cell co-transfected with Histone 
H2B-mCherry and GFP (n = 22) or FAM65B-GFP (n = 27) expressing vectors to complete a division (B and D) or to align chromosomes 
(C) was evaluated by time-lapse microscopy. Statistical analysis: Paired two-tailed Student’s t-test. (E) HeLa cells were co-transfected 
with α-tubulin-GFP and m-Cherry (n = 14) or FAM65B-mCherry (n = 20), and their capacity to form a mitotic spindle was followed by 
time-lapse microscopy.
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onset of stimulation (Figure 4B). This observation is not 
related to cell culture as the level of FAM65B is constant in 
non-stimulated cells. To reveal the functional importance 
of this decrease, we next followed the consequences of 
maintaining FAM65B expression during activation. 
Primary human T cells were transfected with a plasmid 
coding for FAM65B-GFP (or GFP alone as a control), 
activated with anti-CD3 and -CD28 coated beads, and cell 
proliferation was monitored by analyzing cell trace violet 
(CTV) dilution of GFP+ cells. We observed that expression 
of FAM65B totally inhibits the proliferation induced by 
TCR engagement (Figure 4C). ERK phosphorylation 
(Figure 4D) and CD69 expression (Figure 4E) upon TCR 
stimulation was similarly induced in both conditions, 
excluding any major defect in early TCR signaling 
upon FAM65B expression. Again, we also observed 
that addition of an HDAC6 inhibitor on primary T cells 
stimulated with anti-CD3 and -CD28 coated-beads has 
the same effects than FAM65B, leading to an inhibition 
of proliferation with no cell death (Supplementary 
Figure S2B). With a complementary approach, we used 
RNA interference (RNAi) to study the consequences of 
decreasing FAM65B expression prior to TCR stimulation 
of primary human peripheral blood T cells (Figure 5A). 
We observed that FAM65B-depleted cells proliferated 
more than control cells (Figure 5B).
Primary peripheral T cells have a heterogeneous 
capacity to proliferate based on CD45RA expression 
([21] and Supplementary Figure S4). We purified naive 
CD45RA+ (high activation threshold) and CD45RO+ 
(low activation threshold) populations from peripheral 
blood T cells, and sought to determine whether the lower 
activation threshold of CD45RO+ T cells was associated 
with decreased FAM65B expression levels. Indeed, our 
results show that these cells express a lower level of 
FAM65B than naive CD45RA+ cells (Figure 5C). 
We then studied the proliferation of CD45RA+ 
cells upon activation with increasing doses of anti-
CD3 and -CD28 coated-beads after FAM65B depletion. 
For all experiments, the depletion of FAM65B was 
Figure 3: The anti-proliferative property of FAM65B results from its capacity to interfere with HDAC6 and 14.3.3. 
(A) Lysates from HEK293T cells transfected with FAM65B-GFP or FAM65B RL151-152AA-GFP mutant were subjected to a pull-down 
assay using beads bearing GST-RhoA. (B) The proliferation of transfected Jurkat cells with GFP alone (Control: CT) and wild type or 
mutant RL151-152AA forms of FAM65B expression vectors was measured by daily counting the number of viable cells. Results are shown 
as means ± SD of at least three individual experiments. (C) HEK293T cells were transfected with pEF-Myc vector expressing either no 
protein (Control: CT), FAM65B or its mutant S(x5)A form fused to GFP. Whole cell lysates (WCL) and anti-Myc immunoprecipitates were 
analyzed by immunoblotting. (D) The proliferation of transfected Jurkat cells with either GFP alone (Control: CT), wild type or mutant 
S(x5)A of FAM65B expression vectors was measured by counting daily the number of viable cells. Results are shown as means ± SD of 
at least three individual experiments. (E) The proliferation of Jurkat cells co-transfected with mCherry or FAM65B-mCherry and GFP or 
HDAC6-GFP was measured by counting the number of viable cells every day. Results are shown as means ± SD of at least three individual 
experiments. (F) HEK293T cells were co-transfected with HDAC6-GFP, 14.3.3-HA and pEF-Myc vector expressing either FAM65B or its 
mutant S(x5)A form. Whole cell lysates and anti-Myc immunoprecipitates were analyzed by immunoblotting.
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verified by intracellular staining and flow cytometry 
analysis (Supplementary Figure S5). In the absence of 
stimulation, no proliferation was observed. However, 
FAM65B-depleted cells were induced to proliferate at 
sub-optimal doses of activators that induced only marginal 
proliferation of control T lymphocytes expressing 
FAM65B (Figure 5D). These results show that there is an 
inverse correlation between the cellular levels of FAM65B 
and the capacity of human primary T cells to proliferate in 
response to an activation signal. They ultimately suggest 
that the decrease of FAM65B expression is a pre-requisite 
for T-cell proliferation.
DISCUSSION
We show here that FAM65B, a major transcriptional 
target of FOXO1, known as a quiescence factor, inhibits 
the proliferation of transformed cell lines through 
perturbation of mitosis. Our data suggest that this effect 
is linked to the capacity of FAM65B to inhibit the 
HDAC6/14.3.3 cell proliferation control pathway. In 
primary T cells, we observed that FAM65B expression 
regulates cell proliferation. Finally, our results indicate 
that the level of expression of FAM65B might also set the 
activation threshold of sub-populations of T cells.
Our work establishes that inhibition of FAM65B 
expression is required for cell proliferation as its ectopic 
expression in proliferating cells induces cell cycle arrest 
and death. Therefore, FAM65B could be considered as 
a bona fide quiescence factor. It was initially thought 
that cells spontaneously become quiescent. It is now 
believed that quiescence is a cellular state controlled by 
environmental cues and required for tissue physiology, 
as demonstrated for instance in the hematopoietic system 
[22]. As a consequence, much recent work has focused 
on the active regulation of this state [23]. Although the 
link between loss of quiescence and proliferation is 
intuitive, some observations obtained in the T cell model 
are intriguing. Indeed, one notable feature observed upon 
TCR stimulation is a comparatively long time period 
(> 24 h) before the first cell division, as compared with 
the subsequent cell divisions that involve rapid doubling 
(every 5–6 hrs) [24]. The state through which naive T cells 
transit, from quiescence to the entry in the first cell cycle, 
is not fully characterized even if some metabolic events 
have been involved [25]. FAM65B was initially reported 
to be expressed in syncytia, both in placenta and in muscle 
[11, 18, 26]. In syncytia, multinucleated cells result from 
cell-cell fusion induced by endogenous retroviral envelops 
[27, 28]. Interestingly, it has recently been established that 
the cell-cell fusion induced by viruses led to cell cycle 
arrest and senescence, i.e. irreversible quiescence [29].
In addition, terminal differentiation of HL-60 cells led to 
both cell cycle arrest and FAM65B expression [26]. We 
Figure 4: FAM65B expression is inversely correlated with the proliferative potential of activated T cells. Primary human 
T cells were stimulated in vitro for several hours using anti-CD3 and -CD28 coated-beads. FAM65B expression was quantified at both the 
transcript (A) and the protein (B) levels. (C) Primary human T cells were transfected with GFP (Control: CT) or FAM65B-GFP expression 
vector then stained with Cell Trace Violet (CTV) and stimulated in vitro as described in (A) for 4 days. In the histograms, the grey lines 
correspond to the GFP+ cells and the black lines to the GFP- cells. Note that in CT conditions, GFP+ cells proliferate slightly less efficiently 
than GFP- cells. This is likely to be an effect of the transfection per se. (D) ERK phosphorylation and (E) CD69 expression of transfected 
cells stimulated or not with anti-CD3 and –CD28 was analyzed by flow cytometry after 3 minutes and 8 hours of culture, respectively.
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now report that FAM65B is highly expressed in naive T 
lymphocytes, a cell population that is characterized by a 
reversible quiescent state, and is down-regulated upon cell 
cycle entry. The expression of FAM65B can therefore be 
considered as a molecular marker of quiescence, whether 
or not it can be reversed. 
FoxO1 is known to control cell proliferation 
through multiple mechanisms. FoxO factors stabilize G1 
and G2/M checkpoints by the activation of a number of 
cell cycle regulatory proteins, including p130, members 
of the Cip/Kip and INK4 CKI families, cyclin G and 
Gadd45a. In addition, FoxO factors can also facilitate cell 
cycle arrest through the inhibition of the D-type cyclins 
and FoxM, a subgroup of Fox transcription factors that is 
known to positively drive G2/M phase transition [30]. In 
this study, we show that FAM65B, a transcriptional target 
of FOXO1, induces G2/M arrest. As previously proposed 
[12, 18], one mechanism to explain this effect might be 
an inhibition of the microtubule network by FAM65B, 
and especially a regulation of tubulin acetylation by 
FAM65B. Indeed, we know that FAM65B inhibits the 
deacetylase activity of HDAC6, a histone deacetylase 
of class II that functions as a tubulin deacetylase [12]. 
This hypothesis about a role of HDAC6 in the effects of 
FAM65B is further validated by our results showing that 
the cell cycle arrest induced by FAM65B can be overcome 
by an excess of HDAC6. It should also be noted that 
pharmacological inhibitors of HDAC6, which are used 
in clinical trials for the treatment of myeloma [31–33], 
mimic the anti-mitotic effect of FAM65B. In previous 
studies, HDAC6 activity was established as a requirement 
for efficient oncogenic transformation. Without HDAC6 
expression, fibroblasts were more resistant to both 
Ras- and ErbB2-dependent transformations [34]. The 
absence of FAM65B expression in transformed cell lines, 
consecutive to the inhibition of FOXO1 transcriptional 
activity, might also participate in the deregulation of 
HDAC6 required for the transformation process. Thus, as 
observed in our experiments with transformed cells, the 
perturbed mitosis induced by FAM65B could be the result 
of a defective microtubule organization downstream of 
HDAC6, culminating in a failure of the mitotic spindle 
during mitosis. Interestingly, FAM65B was recently 
localized to the plasma membrane of the stereocilia of 
Figure 5: FAM65B expression is inversely correlated with the T cells activation threshold. (A) The efficiency of FAM65B 
knock-down in human primary T cells was checked by immunoblotting with anti-FAM65B and anti-α-tubulin as a loading control. (B) 
Human primary T cells were transfected with control (siCT) or FAM65B (siFAM65B) siRNA, then stained with CTV and stimulated in 
vitro for 3 days using anti-CD3 and -CD28 coated-beads. The proliferation of transfected cells was analyzed by flow cytometry after 3 
days of stimulation. The percentage of cells exhibiting 0, 1, 2, 3, 4 divisions or the addition of them (total) is quantified as the mean ± SD 
obtained from four donors. (C) Naive (CD45RA+) or activated/memory (CD45RO+) populations were purified from peripheral blood 
T cells. FAM65B expression was then analyzed by immunoblotting. (D) Primary human CD45RA+ T cells transfected with siFAM65B 
or siCT were stained with CTV and stimulated in vitro using variable doses of anti-CD3 and anti-CD28 -coated beads. The proliferation 
of the transfected cells was analyzed by flow cytometry after 3 days of stimulation. Results are representative of at least three individual 
experiments
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both inner and outer hair cells, and mutations of FAM65B 
leads to deafness syndromes, suggesting that the lack of 
functional FAM65B could hinder the development of the 
mechanotransduction apparatus, through perturbation of 
the primary cilium [13]. Indeed, HDAC6 has been notably 
implicated in cell proliferation via the regulation of the 
primary cilium [35, 36], which is known to control the 
cell cycle [37].
In addition, our work shows that the phosphorylation 
of FAM65B is required for both this anti-proliferative 
function and the formation of a tripartite complex 
comprised of FAM65B, 14.3.3 and HDAC6. Several 
studies have identified a possible phosphorylation of 
FAM65B not only in the Jurkat leukemic T cell line 
[38], but also in primary mouse neutrophils [10] and T 
lymphocytes [39]. In this latter case, the phosphorylation 
results from PKCη activity [39]. The 14.3.3 scaffolding 
proteins play a critical role in the regulation of cell fate 
through phospho-dependent binding to a large number of 
intracellular proteins. This function can be achieved by the 
formation of multi-protein complexes upon recruitment of 
such proteins or by restricting the access of other ones 
[14]. FAM65B, as a well-known 14.3.3 phosphopeptide 
ligand, contains the consensus sequences RSXpT/SXP and 
RXY/FXpT/SXP. The study by Gao et al. [10], confirmed 
by our results, show that the phosphorylation of FAM65B 
allows its interaction with 14.3.3. Though it cannot be 
excluded that phosphorylated form of FAM65B directly 
interacts with HDAC6, the fact that the FAM65B/HDAC6 
interaction has been observed only in the context where 
the three proteins were present and not detected in our 
yeast two-hybrid screen [9], suggests that 14.3.3 makes a 
link between HDAC6 and FAM65B.
One intriguing feature of our work is the regulation 
of the T cell activation threshold by FAM65B. In T 
lymphocytes, the strength and duration of TCR signaling 
in response to antigen stimulation dictates the magnitude 
and the quality of the primary response [40, 41]. The 
TCR activation threshold, agonist affinity discrimination 
as well as signal termination must therefore be tightly 
regulated. This is achieved through the concerted action of 
multiple positive and negative regulators acting in resting 
or activated T cells. The 14.3.3 scaffolding protein has 
already been involved in the fine tuning of TCR-activation 
through relocalization of several signaling proteins [42–
45], including FoxO1 [46, 47], suggesting a possible 
amplification loop that would keep FoxO1 in the cytosol 
and therefore would maintain FAM65B expression levels 
very low in activated T cells. Although much work will 
have to be done to precisely understand how FAM65B is 
able to set the activation threshold of T cells, it is tempting 
to assume, on the basis of our results, that its capacity to 
control the activity of the 14.3.3/HDAC6 complex could 
participate in this function.
We have already shown that in T lymphocytes, 
FAM65B inhibits cell migration by blocking the GTP 
loading of RhoA [9]. Here, we show that FAM65B has a 
general quiescence promoting activity, which is active in 
resting T cells and controls both proliferation and setting 
of the activation threshold, at least in part through the 
14.3.3/HDAC6 pathway. Therefore, in T cells, FAM65B 
appears as a main effector target of FOXO1 that is able 
to interact with two different targets to control the two 




Human T lymphocytes were purified from the blood 
of healthy donors (Etablissement Français du Sang, Paris, 
France; relevant ethical approvals and consent have been 
obtained for use of human samples, ref E-2075) and 
cultivated as described [7, 9]. The naive (CD45RA+) and 
memory (CD45RO+) T cells were obtained by negative 
depletion on magnetic beads [Anti Human CD45RO 
Particles, Anti Human CD45RA Particles, respectively 
(BD Biosciences). Jurkat cells (gift of G. Crabtree, 
Stanford University, Stanford, CA) were cultivated in 
complete RPMI medium, HeLa (gift of C. Berlioz, Institut 
Cochin, France) and HEK293T cells (ATCC-CRL-3216) 
were cultivated in complete DMEM medium.
Constructs and pharmacological inhibitors
pEGFP-FAM65B plasmids were previously 
described [9]. Mutations of the RhoA interaction domain 
(RL151-152AA) and phosphorylation sites (S(x5)A) 
were constructed by PCR using QuickChange II site-
directed mutagenesis Kit (Agilent) with the primers listed 
in Supplementary Table S1. pmCherry-FAM65B was 
constructed by PCR by introducing the mCherry ORF at 
the AgeI/NotI site of pEGFP-FAM65B. FAM65Bwt and 
S(x5)A Myc constructs were obtained by amplification 
with primers listed in Supplementary Table S1 and by 
introducing FAM65B ORF in pEF vector at the SpeI/
EcoRV sites. plncx-Histone 2B-mCherry and plncx2-
Tubuline-YFP were a kind gift of C. Berlioz (Institut 
Cochin, France) and pEGFP-N1-HDAC6 was purchased 
from Addgene (# 36188). HA-tagged 14.3.3 plasmid was 
a kind gift of JL Andersen (Brigham Young University, 
Provo, UT). HDAC6 specific antagonist CAY-10603 
(Selleckchem) has been described and characterized 
before [47]. Etoposide is a kind gift of R. Donné (Institut 
Cochin, Paris). λ Protein Phosphatase was from Millipore.
Quantitative RT-PCR
Total RNA was prepared using an RNeasy mini 
kit (QIAGEN). cDNA was produced with the Advantage 
RT-for-PCR kit (Clontech Laboratories) using 1 μg total 
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RNA and random hexamer priming in a final volume of 
20 μL. Real-time quantitative PCR was performed using 
the LightCycler FastStart DNA Master plus SYBR Green 
kit (Roche Diagnostics). Genes of interest were detected 
using primers that had been designed with Oligo6 software 
(Molecular Biology Insights) and optimized to generate 
a single amplicon of 80–130 nucleotides. The sequences 
of the primers used in qRT-PCR experiments are in 
Supplementary Table S1.
DNA and RNA interference transfections
HeLa and HEK293T cells were transfected with 
Lipofectamine 2000 (Invitrogen), according to the 
manufacturer’s instructions. Jurkat cells (5 × 106) in 
500 µL of RPMI without phenol red were electroporated 
with 5 μg DNA using the BioRad system (270 V, 950 µF). 
Primary T cells (5 × 106) were nucleofected using the 
Amaxa system (Lonza; kit T, U-014 program) with 5 μg 
DNA or 2 μL of a 100 μM solution of OTP SMARTpool 
RNAi (Dharmacon) directed against human FAM65B or 
non-targeting sequences as a control.
Flow cytometry
Apoptosis was determined by staining with Annexin 
V-PE (BD Pharmingen, PE Annexin V Apoptosis Detection 
kit I) according to the manufacturer’s instructions. 
Proliferation of primary T cells was assessed by 
dilution of Cell Trace Violet kit (Invitrogen). After two 
washes in PBS, cells were resuspended at 106 cells per 
mL in a 5 µM Cell Trace Violet solution. Cells were 
incubated in dark at 37°C for 20 min. After the loading, 
cells were washed with a volume of cold PBS 10% 
FCS corresponding to 5 times the loading volume. Cell 
suspension was collected and dispensed into 96-well 
round-bottom microtiter plates (Falcon; 2 × 105 cells per 
well) and stimulated using anti-CD3/CD28 coated-beads 
(Dynabeads, Life technologies) for 3 days. 
For cell cycle analysis of transfected cells 
(Jurkat and HeLa cells), 106 cells were fixed with 4% 
paraformaldehyde for 10 min, permeabilized with 
0,1% saponin, and incubated with PBS 1 mM EDTA 
Supplementary emented with 50 µg/mL of Propidium 
Iodide (Sigma) and 200 µg/mL of RNAse A (Sigma) for 
30 min at 37°C.
For analysis of ERK phosphorylation in transfected 
PBT, 106 cells were fixed with 4% paraformaldehyde for 
10 min, permeabilized with methanol at –20°C for 1 hour, 
and incubated with anti-ERKP antibody (# 4370, Cell 
Signaling Technology) in PBS 0.2% BSA for 30 min at 
room temperature and then with F(ab’)2-Goat anti-Rabbit 
IgG (H+L) secondary antibody (#A-21246, Thermofisher). 
Cytometry data were obtained using a BD-LSR Fortessa 
flow cytometer (BD Bioscience). Data files were analyzed 
using FlowJo software (TreeStar).
Fluorescence microscopy
Time-lapse microscopy was performed on HeLa 
cells grown on coverslips in a Zeiss Axiovert 200 
microscope at 37°C with a 20× objective (LD Plan 
Neofluar). The camera CoolSnap HQ (Photometrics) was 
used to acquire images. Images were processed using 
ImageJ software.
Biochemistry
Primary T cells were stimulated using anti-CD3/
CD28 -coated beads (1 bead per 5 cells, Dynabeads, 
Life technologies) into 96-well round-bottom microtiter 
plates (Falcon; 2 × 105 cells per well). Collected cells 
were lysed in lysis buffer [20 mM Bicine, pH7.6; 0.6% 
CHAPS complete protease and phosphatase inhibitor 
cocktail (Roche)] for 30 min on ice. Lysates were 
collected after centrifugation at 14,000 rpm for 10 min. 
Protein concentration in supernatants was quantified 
with the Bradford assay. SDS loading buffer was added 
to each sample and then boiled at 100°C for 5 min. An 
equal amount of proteins was loaded on 10% SDS-
PAGE, transferred to nitrocellulose membranes, and 
immunoblotted with anti-FAM65B Ab (Abnova), anti-β-
actin Ab (Sigma), anti-α-tubulin (Santa Cruz) or anti-eIF-
4E (Santa Cruz) followed by a secondary HRP-labeled Ab 
(Jackson ImmunoResearch). Membranes were revealed 
by ECL (GE Healthcare Life Sciences) using a camera 
(Fusion FX7, VilberLourmat). For immunoprecipitation 
experiments, transfected cells were washed in cold 
PBS and lysed in 1 mL lysis buffer [10 mM HEPES pH 
7.5; 150 mM KCl; 0.1%NP-40; 10 µM SAHA (Sigma 
Aldrich); 40 µM Tubacin (Sigma Aldrich); 50 µM 
Nicotinamide (Sigma Aldrich); complete protease and 
phosphatase inhibitor cocktails (Roche)] for 30 min in ice. 
Lysates were collected after centrifugation at 14,000 rpm 
for 10 min. 40 µL of each lysate was saved and used as a 
loading control. 20 µL of EZ myc beads (Sigma Aldrich) 
pre-washed 3 times with lysis buffer were added in the 
lysate and rotated for 2 h at 4°C. After rotating, the beads 
were washed 3 times with lysis buffer and resuspended 
into 100 µL of TBS1X containing 10 µg/mL of myc 
peptide for 30 min at 4°C. 70 µL of the supernatant 
containing the protein complexes without beads/Ab was 
taken off. Each sample was boiled at 100°C for 5 min after 
adding 5× Laemmli buffer, subjected to 12% SDS-PAGE, 
transferred to nitrocellulose membrane and immunoblotted 
with the indicated antibodies. Pull-down assays with 
beads containing GST-tagged RhoA (Cytoskeleton) were 
described in Rougerie et al. [9].
Statistical analysis 
Statistical significance was analyzed by paired 
two-tailed Student’s t-test and expressed as a p value. 
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The number of analyzed samples (n) is indicated. All 
experiments were performed at least as three independent 
experiments. When indicated, standard deviations are 
represented as scale bars on graphs. We used the following 
conventions to illustrate the p value: *0.01 < p < 0.05, 
**0.01 < p < 0.001, ***p < 0.001. ns: not significant.
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